Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.
FIGURE 5

FIGURE 5. From: Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain stem Glioma: A Report from the Pediatric Brain Tumor Consortium.

Association of 2D continuous PET variables and intensity (A) or uniformity (B) of brainstem glioma 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake. There was some evidence of association between 2D continuous PET variables and intensity or uniformity of brainstem glioma 18F-FDG uptake (p-value ≤ 0.05). (WM = White Matter; GM = Gray Matter)

Katherine A. Zukotynski, et al. J Nucl Med. ;52(2):188-195.
2.
FIGURE 6

FIGURE 6. From: Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain stem Glioma: A Report from the Pediatric Brain Tumor Consortium.

Association of uniformity of brainstem glioma 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake with tumor diffusion ratio. There is some evidence that as the uniformity of brainstem glioma 18F-FDG uptake increases the apparent diffusion coefficient decreases (p-value=0.025) suggesting increasing cellularity in the tumor corresponding to 18F-FDG uptake.

Katherine A. Zukotynski, et al. J Nucl Med. ;52(2):188-195.
3.
FIGURE 4

FIGURE 4. From: Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain stem Glioma: A Report from the Pediatric Brain Tumor Consortium.

Association of uniformity of brainstem glioma 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake with progression-free survival (A) (p=0.031) and overall survival (B) (0.086), suggesting that patients with <50% of the tumor with 18F-FDG uptake have more favorable progression-free survival. 18F-FDG uptake >50% of tumor is red line; 18F-FDG uptake ≤ 50% is blue line.

Katherine A. Zukotynski, et al. J Nucl Med. ;52(2):188-195.
4.
FIGURE 3

FIGURE 3. From: Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain stem Glioma: A Report from the Pediatric Brain Tumor Consortium.

Association of intensity of brainstem glioma 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake with progression free survival (blue lines) and overall survival (red lines). Dashed lines represent patients with 18F-FDG Uptake in tumor similar to or greater than gray matter and solid lines represent others. There was no association between intensity of brainstem glioma 18F-FDG uptake, progression free survival (p=0.36) or overall survival (p=0.48).

Katherine A. Zukotynski, et al. J Nucl Med. ;52(2):188-195.
5.
FIGURE 2

FIGURE 2. From: Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain stem Glioma: A Report from the Pediatric Brain Tumor Consortium.

Progression free survival rate (A) and overall survival rate (B) for patients with baseline PET (blue solid line) versus patients without baseline PET (red dashed line). There was no evidence that the subset of children for whom baseline PET was available was biased with respect to progression-free survival (p=0.52) or overall survival distributions (p=0.52).

Katherine A. Zukotynski, et al. J Nucl Med. ;52(2):188-195.
6.

FIGURE 1. From: Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain stem Glioma: A Report from the Pediatric Brain Tumor Consortium.

Illustrative examples of the grading scheme for intensity and uniformity of 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET uptake by brainstem glioma. (A) 12-year-old girl with intensity of brainstem glioma 18F-FDG uptake between normal white and gray matter, the percentage of the tumor demonstrating 18F-FDG uptake <25%(as demonstrated on the FLAIR MRI-marked with red ROI), progression-free survival of 258 days and overall survival of 348 days. (B) 7-year-old boy with intensity of brainstem glioma 18F-FDG uptake greater than normal gray matter, the percentage of the tumor demonstrating 18F-FDG uptake >75% (as demonstrated on the FLAIR MRI marked with red ROI), progression-free survival of 169 days and overall survival of 196 days.

Katherine A. Zukotynski, et al. J Nucl Med. ;52(2):188-195.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk